Generation Bio Co · Q2 2023 earnings

Briefing

Generation Bio's financial performance declined in Q2 2023 with reduced R&D spending but increased G&A expenses, while collaboration revenue was recognized.

Generation Bio reported a net loss of $31.1 million, or $0.47 per share, for the second quarter of 2023. The company's cash position remains strong at $314.1 million, expected to fund operations into 2025. They are focused on demonstrating Factor VIII expression in non-human primates for hemophilia A program.

• Cash, cash equivalents, and marketable securities totaled $314.1 million as of June 30, 2023.
• Research and development expenses were $21.8 million for the quarter ended June 30, 2023.
• General and administrative expenses were $13.0 million for the quarter ended June 30, 2023.
• Net loss was $31.1 million, or $0.47 basic and diluted net loss per share, for the quarter ended June 30, 2023.

Headline financials

Revenue & EPS history

The company is focused on demonstrating Factor VIII expression in non-human primates for its hemophilia A program and continued development of in-vivo targeting to immune cells with its stealth ctLNPs. Its cash position is expected to fund operations into 2025.